Repligen (RGEN) closed at $173.49 on November 6, 2026, up 3.0% from the previous close, on volume of 1,033,772 shares (30-day average 1,364,143).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 26, 2026 | Calendar Put Ratio Spread | 20-Nov-26 120|18-Dec-26 120[3.75x] P | 1,900 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Repligen Issues $1 Billion Convertible Notes, Restructures Debt
TipRanks (Fri, 6-Nov 4:42 PM ET)
Repligen Corporation to Present at Jefferies Global Healthcare Conference
Globe Newswire (Wed, 4-Nov 7:00 AM ET)
Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), OmniAb (OABI) and Incyte (INCY)
TipRanks (Mon, 2-Nov 11:30 AM ET)
TipRanks (Mon, 2-Nov 11:16 AM ET)
RBC Capital Remains a Buy on Repligen (RGEN)
TipRanks (Mon, 2-Nov 10:37 AM ET)
William Blair refreshes stock Conviction List with 5 additions, 3 removals
Seeking Alpha News (Mon, 2-Nov 8:56 AM ET)
Market Chameleon (Fri, 30-Oct 7:51 AM ET)
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
Globe Newswire (Fri, 30-Oct 6:00 AM ET)
Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Globe Newswire (Tue, 27-Oct 7:00 AM ET)
Repligen to Report Third Quarter 2026 Financial Results
Globe Newswire (Tue, 13-Oct 7:30 AM ET)
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Repligen trades on the NASDAQ stock market under the symbol RGEN.
As of November 6, 2026, RGEN stock price climbed to $173.49 with 1,033,772 million shares trading.
RGEN has a beta of 1.30, meaning it tends to be more sensitive to market movements. RGEN has a correlation of 0.11 to the broad based SPY ETF.
RGEN has a market cap of $11.01 billion. This is considered a Large Cap stock.
Last quarter Repligen reported $209 million in Revenue and $.53 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.07.
In the last 3 years, RGEN traded as high as $211.13 and as low as $100.99.
The top ETF exchange traded funds that RGEN belongs to (by Net Assets): IJH, VTI, VB, VBK, VXF.
RGEN has outperformed the market in the last year with a price return of +19.7% while the SPY ETF gained +10.8%. RGEN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +8.8% and -1.9%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
RGEN support price is $162.17 and resistance is $174.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RGEN shares will trade within this expected range on the day.
